Lv1
30 积分 2024-04-23 加入
Immune Checkpoint Inhibitors Rechallenge in Non-Small Cell Lung Cancer: Current Evidence and Future Directions
1天前
待确认
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy
1天前
已完结
Tumour burden and efficacy of immune-checkpoint inhibitors
13天前
已完结
Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies
1个月前
已完结
PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy
1个月前
已完结
Mechanisms of metastatic colorectal cancer
1个月前
已完结
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2个月前
已完结
Continuing immune checkpoint inhibitors after progression: Real-world patterns of care and outcomes in second-line treatment for extensive-stage small-cell lung cancer
2个月前
已完结
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
2个月前
已完结
皖公网安备34019202002308
